Longitudinal multi-center molecular biomarker registry for blood cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The TEMPUS AQUARIUS registry is a non-interventional, longitudinal, multi-center effort to collect paired molecular (multi-omic) and clinical data from patients with acute myeloid leukemia (AML) and follicular lymphoma. Participants provide serial blood draws and leftover tissue or bone marrow aspirates during routine care, and clinical outcomes are captured from medical records. Samples will undergo next-generation sequencing and other molecular analyses to link biomarkers with real-world outcomes. The registry does not change or prescribe treatment and is designed to build a large longitudinal dataset for biomarker discovery.

Why it matters

Who can join: the full rules

All Cohorts Inclusion Criteria:

1. Willing and able to participate in the research and provide biospecimens
2. Willing and able to provide informed consent

Cohort 001 Inclusion:

1. Have documented diagnosis of AML according to the World Health Organization (WHO) classification
2. Secondary AML is allowed

Cohort 002 Inclusion:

1. Histologically confirmed diagnosis of Follicular Lymphoma (Subgroups A-D)
2. Submission of baseline sample representative of current disease per laboratory manual (Subgroups A-D)
3. 002A (Newly Diagnosed Active Observation): On active observation for 6 more or less, or intended for active observation
4. 002B (Newly Diagnosed, High Risk): Intended for first line treatment
5. 002B (Newly Diagnosed, High Risk): Meets the criteria for high risk by any of the following: Follicular Lymphoma Inernational Prognostic Index (FLIPI) High Risk, Groupe d'Etude des Lymphomes Follicularies (GELF) High Tumor Burden, Lactate Dehydrogenase (LDH) above the upper limit of normal (ULN)
6. 002C (Relapsed / Refractory High Risk POD24 FL): Documented progression of disease within 24 months (POD24) of first line follicular lymphoma treatment, prior to second line treatment
7. 002D (Transformed FL): Pathologically confirmed transformation

All Cohorts Exclusion Criteria:

1\. Not willing or able to adhere with the study procedures

Cohort 001:

1\. Have received any prior therapy intended for standard of care (SoC) treatment of AML

Cohort 002:

1. 002A: Received prior treatment for follicular lymphoma
2. 002A: Diagnosed with High Risk follicular lymphoma by any of the following definitions: FLIPI High Risk, GELF High Tumor Burden, LDH above ULN
3. 002A: Resected patients with NED
4. 002B: Intended for active observation
5. 002B: Received prior treatment for follicular lymphoma

Where it's running

• University of Iowa Hospital and Clinics
  Iowa City, Iowa, United States Recruiting
• The Center for Cancer and Blood Disorders
  Bethesda, Maryland, United States Recruiting
• Washington University in St. Louis
  St Louis, Missouri, United States Recruiting
• Cancer Care Specialists of Reno
  Reno, Nevada, United States Recruiting
• University of Rochester
  Rochester, New York, United States Recruiting
• Novant Health Weisiger Cancer Institute
  Charlotte, North Carolina, United States Recruiting

Study contacts

• Principal investigator: Michael Thompson, MD, PhD, FASCO — Tempus AI
• Study coordinator: Aquarius Clinical Study Manager
• Email: aquarius@tempus.com
• Phone: 800-739-4137

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Rocbrutinib and Lacutoclax in B-cell cancers

  This study tests whether Rocbrutinib plus Lacutoclax can help adults with B-cell malignancies, including CLL/SLL, MCL, DLBCL, FL, WM, who have had prior therapy or are treatment-naïve under specific criteria.

  Recruiting Phase 1/2 Guangzhou Lupeng Pharmaceutical Company LTD. · Tianjin · NCT07609862

• SCTB35 plus Lenalidomide for relapsed or refractory follicular lymphoma

  This trial tests whether SCTB35 given with Lenalidomide can help people whose follicular lymphoma has come back or stopped responding to prior treatment.

  Recruiting Phase 3 Sinocelltech Ltd. · Beijing, Beijing Municipality · NCT07562022

• CT1182 CAR‑T infusion for adults with relapsed or refractory B‑cell non‑Hodgkin lymphoma

  This trial tests whether a CT1182 CAR‑T cell infusion is safe and can help adults 18–75 with relapsed or refractory B‑cell non‑Hodgkin lymphoma.

  Recruiting Early Phase 1 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07548697

• NexCAR19 (Talikabtagene Autoleucel) for relapsed or refractory B‑cell leukemias and lymphomas

  This trial will test modified versions of a patient's own T cells (NexCAR19/Talikabtagene Autoleucel) to see if they can control relapsed or refractory B‑cell leukemias and lymphomas in adults.

  Recruiting at 3 sites Phase 2/3 Health Institutes of Turkey · Ankara and 3 other locations · NCT07502118

• MDX2003 for adults with relapsed B‑cell lymphomas

  This trial will test MDX2003 in adults with relapsed or refractory B‑cell lymphomas whose tumors are CD19 or CD20 positive to see if it is safe and can shrink tumors.

  Recruiting at 7 sites Phase 1/2 ModeX Therapeutics, An OPKO Health Company · Richmond, Victoria and 6 other locations · NCT07249905

• Maintenance venetoclax plus subcutaneous cytarabine for fit adults with AML

  This trial will test whether maintenance venetoclax combined with subcutaneous cytarabine helps keep remission longer in fit adults (18–60) with AML who achieved complete remission but cannot get a bone marrow transplant right away.

  Recruiting at 2 sites Sohag University · Sohag and 1 other locations · NCT07244367

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.